DK1948219T3 - Vegf-analoger og fremgangsmåder til anvendelse - Google Patents

Vegf-analoger og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK1948219T3
DK1948219T3 DK06836213T DK06836213T DK1948219T3 DK 1948219 T3 DK1948219 T3 DK 1948219T3 DK 06836213 T DK06836213 T DK 06836213T DK 06836213 T DK06836213 T DK 06836213T DK 1948219 T3 DK1948219 T3 DK 1948219T3
Authority
DK
Denmark
Prior art keywords
glu
leu
ser
arg
lys
Prior art date
Application number
DK06836213T
Other languages
English (en)
Inventor
Mariusz W Szkudlinski
Bruce D Weintraub
Original Assignee
Trophogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trophogen Inc filed Critical Trophogen Inc
Application granted granted Critical
Publication of DK1948219T3 publication Critical patent/DK1948219T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Modificeret vaskulær endothelial vækstfaktor (VEGF) omfattende mindst en mutation som forårsager den modificerede VEGF til at agere som en receptorantagonist, hvor mutationen resulterer i en reduktion i bioaktivitet sammenlignet med vildtype VEGF, og hvor mutationen er en basisk aminosyre-substitution ved en position svarende til position 83 af SEQ ID Nr. :4, hvor substitutionen er valgt fra gruppen bestående af I83K og I83R.
2. VEGF-receptorantagonist ifølge krav 1, hvor antagonisten omfatter en eller flere yderligere basiske aminosyresubstitutioner svarende til gruppen bestående af positioner 44, 67, 72, 73 og 87 af SEQ ID Nr. :4, hvor den yderligere substitution er en eller flere substitutioner valgt fra gruppen bestående af E72R, E73R, E72K, E73K, E44R, E44K, Q87K, Q87L og E67K.
3. VEGF-receptorantagonist ifølge krav 1 og 2 endvidere omfattende en eller flere mutationer der forhindrer neutrophilin-1 binding, og endvidere omfattende en eller flere basiske aminosyresubstitutioner valgt fra gruppen bestående af E44, E67, E72, og Q87 af SEQ ID Nr.:4.
4. VEGF-receptorantagonist ifølge krav 1 og 2, hvor antagonisten omfatter en eller flere yderligere aminosyresubstitutioner i aminosyrer svarende til positionerne 111-165 af SEQ ID Nr.: 4 hvilke forhindrer neurophilin-1 binding, hvor substitutionen er ved positionen svarende til C146 eller C160 af SEQ ID Nr.: 4 og hvor substitutionen er valgt fra gruppen bestående af C146S og C160S.
5. VEGF-receptorantagonist ifølge krav 1 og 2, hvor antagonisten omfatter en eller flere yderligere aminosyresubstitutioner hvilke reducerer eller forhindrer proteasenedbrydning af antagonisten, hvor den ene eller flere yderligere aminosyresubstitutioner er valgt fra gruppen af positioner svarende til positionerne Alll og A148 af SEQ ID Nr.:4, hvor substitutionen er en eller flere valgt fra gruppen bestående af Al IIP og A148P.
6. VEGF-receptorantagonist ifølge krav 1, hvor antagonisten er udtrykt som fusionprotein omfattende en eller flere VEGF-subunits, hvor VEGF-receptorantagonisten yderligere omfatter et toksin.
7. VEGF-receptorantagonist ifølge krav 1 hvor antagonisten er udtrykt som en homodimer eller heterodimer, hvor en eller begge subunits af homodimeren eller heterodimeren indeholder mindst én mutation.
8. VEGF-receptorantagonist ifølge krav 6, hvor toksinet er valgt fra gruppen bestående af Pseudomonas exotoxin (PE), et Diphtheria toksin (DT), ricintoksin, abrintoksin, anthraxtoksin, shigatoksin, botulismetoksin, tetanustoksin, koleratoksin, maitotoksin, palytoksin, ciguatoksin, textilotoksin, batrachotoksin, alfa cono-toksin, taipoxin, tetrodotoksin, alfa tityustoksin, saxitoksin, anatoksin, microcystin, akonitin, exfoliatin toksiner A, exfoliatin B, et enterotoksin, toksisk choksyndromtoksin (TSST-1), Y. pestis toksin og gas koldbrand toksin.
9. VEGF-receptorantagonist ifølge krav 7 og 8, hvor mindst en af subunits er en VEGF-A subunit, VEGF-B subunit, en VEGF-C subunit, VEGF-D subunit eller en PIGF subunit, hvor VEGF-A subunitten er valgt fra gruppen bestående af VEGFi65, VEGFiesb, VEGFm, VEGF145, VEGF148, VEGFiss, VEGFisg, og VEGF206.
10. VEGF-receptorantagonist ifølge krav 1-9, hvor angiogenese er mindst delvist hæmmet.
11. VEGF-receptorantagonist ifølge krav 1, hvor en eller begge subunits af VEGF'en omfatter en modifikation til at forlænge halveringstid, hvor modifikationen til at forlænge halveringstid er en eller flere modifikationer valgt fra gruppen bestående afen N-terminalforlængelse, en C-terminalforlængelse og pegylering.
12. VEGF-receptorantagonist ifølge krav 1, hvor VEGF-receptorantagonist er VEGFiesb receptorantagonist omfattende en eller flere yderligere mutationer valgt fra gruppen bestående af E44B, E67B, E72B, E73B, og Q87B af SEQ ID Nr.: 13, hvor B er en basisk aminosyre.
13. Farmaceutisk sammensætning omfattende VEGF-receptorantagonist ifølge krav 1-12.
14. Farmaceutisk sammensætning omfattende VEGF-receptorantagonist ifølge krav 1-12 til anvendelse i behandling afen patient diagnosticeret med a) cancer, hvor canceren er en solid tumorcancer valgt fra gruppen bestående af blære, bryst, lever, knogle, nyre, tarm, æggestok, prostata, bugspytkirtel, lunge, hjerne, og hud; eller b) en angiogenese-associeret øjensygdom, hvor den angiogenese-associerede øjensygdom er valgt fra gruppen bestående af retinopati af præmaturitet, diabetisk retinopati, retinal veneokklusion, makulær degeneration, og neovaskularisering; eller c) en angiogenese-relateret sygdom eller tilstand, hvor den angiogenese-relaterede tilstand er valgt fra gruppen bestående af hæmangiomer, rheumatoid arthritis, osteoarthritis, septisk arthritis, astma, atherosclerose, idiopatisk lungefibrose, vaskulær restenose, arteriovenøs misdannelser, meningiomer, neovaskulær glaukom, psoriasis, Kaposi's syndrom, angiofibrom, hæmofiliske led, hypertrofiske ar, Osler-Weber syndrom, pyogent granulom, retrolental fibroplasia, sklerodermi, trakom, von-Hippel-Lindau sygdom, vaskulære adhesionspatologier, synovitis, dermatitis, uforklarlig ufrugtbarhed hos kvinder, endometriose, uforklarlig ufrugtbarhed hos mænd, pterygium, sår, betændelse, skindsår, gastriske sår, og ulcus duodeni.
DK06836213T 2005-10-06 2006-10-06 Vegf-analoger og fremgangsmåder til anvendelse DK1948219T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72391705P 2005-10-06 2005-10-06
US80810606P 2006-05-25 2006-05-25
PCT/US2006/039181 WO2007044534A2 (en) 2005-10-06 2006-10-06 Vegf analogs and methods of use

Publications (1)

Publication Number Publication Date
DK1948219T3 true DK1948219T3 (da) 2015-03-30

Family

ID=37943397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06836213T DK1948219T3 (da) 2005-10-06 2006-10-06 Vegf-analoger og fremgangsmåder til anvendelse

Country Status (13)

Country Link
US (3) US8759285B2 (da)
EP (3) EP2447280A3 (da)
JP (2) JP5567271B2 (da)
KR (1) KR20080082608A (da)
AU (1) AU2006302345B2 (da)
CA (1) CA2625395A1 (da)
DK (1) DK1948219T3 (da)
ES (1) ES2533466T3 (da)
HK (1) HK1203527A1 (da)
PL (1) PL1948219T3 (da)
RU (1) RU2008118000A (da)
TW (1) TW200732347A (da)
WO (1) WO2007044534A2 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3214620B2 (ja) 1990-02-10 2001-10-02 株式会社日立製作所 燃料噴射装置用空気制御装置
US20110294683A1 (en) * 2008-10-30 2011-12-01 Centre de Recherche Public de la Sant'e Biomarkers
BRPI0918211A2 (pt) * 2008-12-23 2015-12-08 Genentech Inc métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
WO2010102380A1 (en) * 2009-03-12 2010-09-16 National Research Council Of Canada Potent vegf antagonists
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
KR101337767B1 (ko) * 2011-07-26 2013-12-09 서울대학교산학협력단 Ｖｅｇｆ 발현을 증가시키는 신규한 펩타이드 및 이를 함유하는 약학적 조성물
PT2755600T (pt) 2011-09-16 2021-04-19 Forsight Vision4 Inc Aparelhos de troca de fluidos
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
ES2648487T3 (es) 2012-04-27 2018-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antagonistas de factor de crecimiento endotelial vascular y métodos para su uso
FR2990352A1 (fr) * 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
WO2014117053A1 (en) * 2013-01-27 2014-07-31 The Cleveland Clinic Foundation Anti-angiogenic vegf-ax isoform
US20160022774A1 (en) * 2013-03-12 2016-01-28 Moderna Therapeutics, Inc. Diagnosis and treatment of fibrosis
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
RU2016117275A (ru) 2013-11-01 2017-12-04 Сфериум Биомед С.Л. Тельца включения для трансдермальной доставки терапевтических и косметических средств
EP3096769A1 (en) * 2014-01-21 2016-11-30 University of Helsinki Therapeutic use of vegfr-3 ligands
ES2803102T3 (es) 2014-07-15 2021-01-22 Forsight Vision4 Inc Dispositivo de administración de implante ocular
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
CN110478119B (zh) 2014-11-10 2022-04-15 弗赛特影像4股份有限公司 可膨胀药物递送装置和使用方法
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
CN113017981B (zh) 2016-04-05 2023-07-25 弗赛特影像4股份有限公司 药物递送装置
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN111655206B (zh) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
CN114269792B (zh) * 2019-06-25 2025-08-08 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
WO2021105368A1 (en) * 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of neuropilin antagonists for the treatment of endometriosis
CN112138142B (zh) * 2020-10-09 2021-08-24 南京大学 微囊藻毒素-rr在用于制备预防或治疗肾纤维化疾病的药物中的应用
EP4237434A1 (en) * 2020-10-28 2023-09-06 Centre National de la Recherche Scientifique (CNRS) New splice variant isoform of vegf
US20230220026A1 (en) * 2022-01-12 2023-07-13 National Yang Ming Chiao Tung University Nucleic acid carrier for producing the single-chain vegf fusion protein with high physiological stability and dimeric efficiency, preparation method thereof, and use thereof
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
DK0555229T3 (da) 1990-07-31 1996-08-19 Liposome Co Inc Akkumulation af aminosyrer og peptider i liposomer
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) * 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US6361992B1 (en) 1996-05-08 2002-03-26 The United States Of America As Represented By The Department Of Health And Human Services Thyroid stimulating hormone superagonists
EP1283268A3 (en) * 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor D (VEGF-D)
US6271436B1 (en) 1996-10-11 2001-08-07 The Texas A & M University System Cells and methods for the generation of transgenic pigs
US6750044B1 (en) * 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
US6281408B1 (en) 1998-02-20 2001-08-28 Thomas Jefferson University Efficient method for production of compound transgenic animals
EP1115866A1 (en) * 1998-09-22 2001-07-18 University of Maryland at Baltimore Cystine knot growth factor mutants
AU775956B2 (en) * 1998-11-02 2004-08-19 Otago Innovation Limited Vascular endothelial growth factor-like protein from ORF virus NZ2 binds and activates mammalian VEGF receptor-2
AU5023300A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor variants
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US20070184023A1 (en) * 2003-10-30 2007-08-09 Pharmexa A/S Method for down-regulation of vegf
WO2005072417A2 (en) * 2004-01-27 2005-08-11 The Ohio State University Research Foundation Vascular endothelial growth factors and methods of their use
US9905908B2 (en) 2014-01-14 2018-02-27 Luxshare Precision Industry Co., Ltd. Antenna structure with proximity sensor

Also Published As

Publication number Publication date
HK1203527A1 (en) 2015-10-30
EP2799446A1 (en) 2014-11-05
US20140308264A1 (en) 2014-10-16
JP2009511492A (ja) 2009-03-19
PL1948219T3 (pl) 2015-07-31
JP5567271B2 (ja) 2014-08-06
KR20080082608A (ko) 2008-09-11
US8759285B2 (en) 2014-06-24
EP1948219B1 (en) 2014-12-24
ES2533466T3 (es) 2015-04-10
WO2007044534A3 (en) 2009-04-23
AU2006302345A1 (en) 2007-04-19
EP2447280A2 (en) 2012-05-02
JP2013177458A (ja) 2013-09-09
US20100216702A1 (en) 2010-08-26
CA2625395A1 (en) 2007-04-19
RU2008118000A (ru) 2009-11-20
AU2006302345B2 (en) 2013-09-05
EP2799446B1 (en) 2016-05-11
EP1948219A4 (en) 2009-10-28
JP5840650B2 (ja) 2016-01-06
US9078860B2 (en) 2015-07-14
US20150274793A1 (en) 2015-10-01
TW200732347A (en) 2007-09-01
WO2007044534A2 (en) 2007-04-19
EP1948219A2 (en) 2008-07-30
EP2447280A3 (en) 2012-06-20

Similar Documents

Publication Publication Date Title
DK1948219T3 (da) Vegf-analoger og fremgangsmåder til anvendelse
US20060172941A1 (en) Anti-angiogenic peptides and methods of use thereof
US20090047335A1 (en) Anti-angiogenic peptides and methods of use thereof
US10695404B2 (en) Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
EP1151102B1 (en) Glycosylated leptin compositions and related methods
KR20130004568A (ko) 항-전이성 요법에서 ａｘｌ 신호전달의 저해
CA2210644A1 (en) Ligands for eph-like receptors
JP2003535037A (ja) 炎症を治療する方法
JP2000507456A (ja) 拮抗的特性を有する血管内皮細胞増殖因子の変異体
CZ2001643A3 (cs) Exprese a export inhibitorů angiogeneze ve formě imunofúzinů
USRE49280E1 (en) TGFbeta type II-type III receptor fusions
GB2490655A (en) Modulators of tissue transglutaminase
AU2013213745B2 (en) VEGF analogs and methods of use
CN101501065A (zh) Vegf类似物及使用方法
US20170166624A1 (en) TGFß TYPE II-TYPE III RECEPTOR FUSIONS
JP2002335972A (ja) インスリン受容体関連受容体結合蛋白質及びその利用
US20230091105A1 (en) Chimeric fusions between c4-binding protein c-terminal segment and angiopoietin-1 fibrinogen-like domain as angiopoietin mimetics and tie2 agonists to treat vascular diseases